Hey there, bargain hunter.
This morning, Ionis Pharmaceuticals got ambushed by its own data.
AstraZeneca and Ionis Pharmaceuticals’ antisense therapeutic Wainua failed to show significant cardiovascular benefit in a Phase 3 study of patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). The trial was called CARDIO-TTRansform. The companies revealed only that Wainua, when added to standard of care, did not meet the primary efficacy endpoint — a composite of cardiovascular mortality and recurrent cardiovascular clinical events versus placebo after up to 140 weeks of follow-up.
The market did not wait for a press conference.
Shortly after the open, AstraZeneca was down 7%, while Ionis took a 20% hit. Meanwhile, shares for rivals Alnylam and BridgeBio were up 10% and 15%, respectively. That is not a subtle signal. That is the market repricing a competitive landscape in real time.
Why This Matters
ATTR-CM is not a niche disease. It is a progressive and often underdiagnosed heart condition caused by misfolded transthyretin protein building up in the heart. AstraZeneca estimates that 300,000 to 500,000 people live with the condition worldwide. The treatment market for this disease has already produced one of pharma’s more extraordinary revenue stories.
Current approved treatments for ATTR-CM — Pfizer’s Vyndamax, BridgeBio’s Attruby, and Alnylam’s Amvuttra — are all at or near blockbuster sales status, with Pfizer’s market-leading drug pulling in almost $6.4 billion in annual revenue. Wainua was supposed to enter that room. It did not make it through the door.
A Financial Times report suggested that peak sales for the drug will now be in the region of $4 billion — still meaningful, but short of the $6.5 billion forecast before the CARDIO-TTRansform failure. That $2.5 billion gap is now available for competitors to absorb.
Slight tangent, but it matters: ATTR-CM drugs are not interchangeable. Mechanism differences are real. Alnylam’s Amvuttra is an injectable RNA silencer. Pfizer and BridgeBio sell oral stabilizers. While Amvuttra carries a differentiated clinical profile, Pfizer’s and BridgeBio’s therapies have the advantage of oral administration and comparatively lower list prices — factors that influence prescribing decisions. Wainua was also an injectable silencer. Its failure does not condemn the silencer class broadly, but it does raise questions about trial design that the August data readout will need to answer.
The Winners Are Already Moving
Amvuttra generated $889.9 million in global sales in the first quarter of 2026, representing 187% year-over-year growth. That figure accounted for 76% of Alnylam’s total revenues — driven by increased patient demand, mainly in ATTR-CM. Alnylam was already the fastest-growing name in this space. Today’s failure from its closest silencer-class rival just cleared a lane it did not need cleared.
BridgeBio’s Attruby surpassed analyst expectations by generating $180.6 million in Q1 2026 revenues — up 24% from the same quarter in 2025. With Wainua now sidelined in cardiomyopathy, the oral stabilizer camp looks more durable heading into the back half of the year.
The failure removes, at least for now, a potential competitor to ATTR-CM drugs from Pfizer, BridgeBio, and Alnylam. Their positions in the market look materially stronger after this miss.
The Ionis Problem
Here is where it gets complicated for bargain hunters considering the wreckage.
Wainua is already approved for the hereditary ATTR polyneuropathy form of the disease, bringing in more than $210 million in sales last year and earning Ionis around $49 million in royalty revenue. That approved business does not disappear. But the cardiomyopathy expansion was the growth thesis. Without it, Ionis just became a smaller story with a very large stock drop baked in before the open.
The failure is described as surprising by Stifel analysts, who noted that TTR silencers are known to be effective in the polyneuropathy indication. That surprise element matters. The sell-off may be pricing in more damage than the science actually justifies — or the market is right and the cardiomyopathy application of this drug class is harder than it looks. Nobody knows yet.
AstraZeneca and Ionis plan to analyze the full dataset and share results at the European Society of Cardiology Congress in August 2026. That is the next real information event. Until then, the investment case for Ionis is incomplete.
What Investors Should Watch Next
Amvuttra is expected to reach $4.4 billion in projected sales by 2030, according to GlobalData. That projection just got a little more credible. For Alnylam specifically, the bounce today is real, but the stock had already fallen roughly 30% year-to-date before this catalyst. Today’s move is welcome. Whether it marks a turning point depends on whether Amvuttra can sustain its prescription momentum through a three-way competition where it is both the most expensive and the only injectable.
For Ionis, the August ESC data presentation is the first real chance to understand whether this was a trial execution problem, a patient selection issue, or a genuine ceiling for the drug in this indication. The answer changes the entire valuation math.
The market did not wait for nuance this morning. Whether that creates an opportunity in the wreckage or just a value trap — that question does not have a clean answer today.
